Palisade Bio Inc. Stock
Palisade Bio Inc. Stock
Based on 2 Buy predictions and 1 Sell predictions the sentiment towards Palisade Bio Inc. is rather balanced.
With a target price of 14 € there is potential for a 4003.17% increase which would mean more than doubling the current price of 0.34 € for Palisade Bio Inc..
Our community identified positive and negative aspects for Palisade Bio Inc. stock for the coming years. 1 users see the criterium "Company culture" as a plus for the Palisade Bio Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Palisade Bio Inc. in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Palisade Bio Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Palisade Bio Inc. | - | - | - | - | - | - | - |
| Pacira Pharmaceuticals | 1.900% | 4.902% | 4.902% | 14.439% | 15.676% | -49.528% | -53.275% |
| Rockwell Medical Inc. | -0.990% | -5.729% | -2.742% | -59.451% | -60.417% | -14.194% | -92.157% |
| Twist Bioscience Corp | -2.080% | -5.009% | -4.111% | -41.759% | -42.357% | 8.611% | -77.470% |
Comments
Palisade Bio (NASDAQ:PALI) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Show more
Ratings data for PALI provided by MarketBeat
Palisade Bio (NASDAQ:PALI) was upgraded by analysts at Wall Street Zen to a "sell" rating.
Show more
Ratings data for PALI provided by MarketBeat
Palisade Bio, Inc. (NASDAQ: PALI) had its "buy" rating re-affirmed by analysts at Brookline Capital Management. They now have a $16.00 price target on the stock.
Show more
Ratings data for PALI provided by MarketBeat